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The aim of the study was to investigate the relationship between the vitamin D content, melatonin 
and the characteristics of pineal gland calcifications in patients with malignant tumors of the bones 
of the lower extremities. Vitamin D deficiency and pineal gland calcifications are observed in almost 
100 % of patients with malignant tumors of the lower extremities’ bones. The high heterogeneity of 
calcifications and its dynamics during the treatment of patients may indicate the processes of their 
litholysis and dissolution.  
 _______________________________________________________________________________ 
Introduction 
The pineal gland, located in the geometric 
center of the human brain, is an organ of the 
diffuse endocrine system. Melatonin (5-
methoxy-N-acetyltryptamine) is the main 
hormone of the gland (80 % of the total systemic 
melatonin), an endogenous integrator, chrono 
modulator and regulator of the body's circadian 
rhythms. The maximum secretion of melatonin is 
observed at night, the minimum – during the day. 
Melatonin has, to varying degrees, a dose-
dependent antistressor, sedative, 
neuroprotective, geroprotective, antidepressant, 
antioxidant, antitumor, antiapoptotic (in normal 
cells), proapoptotic (in cancer cells), oncostatic, 
immunostimulating, hepatoprotective, 
geroprotective, antihypertensive, anti-
inflammatory, moderate contraceptive (for 
women) action [1,2]. Melatonin regulates 
neuroendocrine functions, respiratory rate, 
reproductive function; osteogenic differentiation 
of mesenchymal stem cells, formation and 
protection of bones; modulates the activity of 
bone-forming osteoblasts and bone-resorbing 
osteoclasts; reduces pain sensitivity; influences 
intracellular calcium content [2,3].  However, we 
should note that most of these properties of 
melatonin are debatable [1].  
Calcium plays a central role in initiating 
a cellular response, as it participates in all known 
cell effector systems. The difference is only in 
the share contribution of Ca+2 – the effector 
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system and in the source of calcium mobilization. 
Absolutely essential for any cell, calcium 
becomes a cellular toxin at its high concentration. 
An excessive increase in the concentration of 
calcium in the cytoplasm leads to dysfunction 
and cell death [4]. 
Cemeteries (possibly used sometimes as a 
depot) of calcium are observed in almost all 
organs and tissues [5]: gallbladder, kidneys, 
prostate, salivary glands stones, calcifications of 
the brain, heart valves, carotid and coronary 
arteries, lungs, heterotopic idiopathic ossification 
of muscles, tendons, ligaments, joint capsules, 
enterolitis, coprolitis, rhinolitis. 
Deposition of mineral salts (ectopic 
calcification – the process is certainly 
pathological) in the form of solid calcifications is 
observed in almost all organs and tissues [4,5], 
but the pineal gland has the highest level of 
calcification among all organs and tissues of the 
human body. The incidence of pineal 
calcifications increases with age: from 2 % at age 
0-9, 32 % at age 10-19, 53 % in age groups of 20-
29, 8 3% in age groups over 30 and 99 % in age 
groups over 70 years old [5]. Pineal calcification 
is an active process and resembles bone 
formation by a number of signs [6]. This process 
involves mesenchymal stem cells and melatonin. 
Pineal calcification is a marker of aging in the 
body and is associated with evidence so far only 
with Alzheimer's disease and schizophrenia [7], 
although more recently calcifications were called 
physiological or non-pathogenic pineal gland 
calcifications [6]. The relationship of pineal 
calcification with melatonin synthesis violation 
and development of diseases of the central 
nervous system and other organs and systems of 
the body is being studied in the researches [7]. 
A typical participant in the normal 
formation of bones [6] and, possibly, 
calcifications of many localizations [8] is vitamin 
D, which has antiproliferative, antibacterial, anti-
inflammatory (anticytokine), 
immunomodulatory, normoglycemic (insulin), 
antidepressant, analgesic, anabolic, lipolytic, 
organo protective, hypotensive action; regulates 
apoptosis, angioneogenesis. Epidemiological 
and experimental data have shown that low levels 
of vitamin (hormone) D are closely associated 
with overall mortality, the development of 
cardiovascular and oncological diseases (mainly 
breast, prostate, colon cancer), arterial 
hypertension, sarcopenia, metabolic syndrome, 
and insulin resistance and diabetes mellitus types 
1 and 2 in adults [9,10].  
The aim of the study was to investigate 
the relationship between the vitamin D content, 
melatonin and the characteristics of pineal gland 
calcifications in patients with malignant tumors 
of the bones of the lower extremities. 
Material and research methods 
The study included the following groups 
of patients: 1 – control group, 22 practically 
healthy male patients without chronic diseases at 
the age from 36 to 55 years; 2A group – 19 male 
patients with benign tumors (aneurysmal bone 
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cyst, enchondroma, chondroblastoma, 
osteoblastoma, giant cell bone tumor)  at the age 
from 41 to 59 years before treatment; 2B group  
– 19 male patients with benign tumors of the 
proximal/distal femur and simultaneous 
arthroplasty at the age from 39 to 52 years after 
treatment; 3A group – 28 male patients with 
malignant tumors (malignant giant cell bone 
tumor, osteosarcoma, chondrosarcoma, 
fibrosarcoma, Ewing's sarcoma, periosteal and 
paraostal sarcomas, bone lymphoma) of the 
lower extremity bones at the  age from 38 to 60 
years before treatment; 3B group – 21 male 
patients with malignant tumors after radical 
removal of a malignant tumor of the 
proximal/distal femur and simultaneous 
endoprosthetics at the age from 44 to 60 years 
during stable remission; 3C group – 16 male 
patients at the age from 37 to 56 years with 
recurrence and/or metastasis. 
Patient selection criteria for the study: 
age from 36 to 60 years; absence of osteoporosis; 
no pain syndrome, normal renal function (the 
permissible level of exceeding the upper limit of 
the reference values of creatinine is not more 
than 2.5) and liver (biochemical parameters of 
bilirubin, alanine aminotransferase, aspartate 
aminotransferase not exceeding the upper limit 
of the norm by more than 2.5 times); general 
somatic status on the Karnofsky scale is not less 
than 90 %; body mass index – 18.5-25 kg/m²; 
polymorbidity. 
Criteria for excluding patients from 
the study: severe condition of the patient 
(Karnovsky index below 50 %); a history of 
mental illness; signs of renal or hepatic failure 
(ALT/AST level more than 100 U/L; creatinine 
more than 220 μmol/L); low hematological 
parameters (hemoglobin below 90 g/l; the initial 
number of leukocytes less than 3.0 thousand and 
platelets less than 50.0 thousand in the peripheral 
blood); violation of the dim light regime in the 
evening (twilight lighting), night wakefulness; 
the presence of an active infectious process; 
clinical signs of circulatory failure (peripheral 
edema, severe shortness of breath due to 
decompensation of chronic diseases of the 
cardiovascular system), cardiac arrhythmias; use 
of narcotic analgesics for pain relief. 
Biochemistry. The blood serum 
melatonin content was measured by the enzyme 
immunoassay with reagent kits (№ RE54021) 
from IBL-Hamburg GmbH (Hamburg, 
Germany). The detection limit for melatonin is 
1.6 pg/ml, the intra-assay coefficient of variation 
is 4.4 %, and the inter-assay coefficient of 
variation is 7.1 %. 
The content of vitamin 25(OH)D (25-
hydroxycalciferol) in blood serum was 
determined by the immunochemiluminescence 
method on an automatic analyzer ARCHITECT 
25-OH Vitamin D Controls. The detection limit 
is 2.1 ng/ml, the coefficient of variation within 
the assay is 5.2 %, the coefficient of variation 
between assays is less than 7 %. 
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Patient stratification (in addition to the 
study design) was carried out according to the 
classification of vitamin D content [10]: 
deficiency – <20 ng/ml (50 nmol/l); suboptimal 
level – 20-30 ng/ml (50-75 nmol/l); optimal level 
(target status) – 30-50 ng/ml (75-125 nmol/l); 
high content – 50-100 ng/ml (125-250 nmol/l); 
dangerous level – > 100 ng/ml (250 nmol/l). 
Blood sampling was carried out on an 
empty stomach at 7 am, in winter, before 
diagnostic procedures and taking medications. 
Blood samples were taken at 12 noon, 1 and 2 
a.m. (when using a bedside lamp with 
illumination of 10 lux in lying position, 8 a.m. 
(December 2019 – January 2020), from the 
median cubital vein through a pre-installed 
catheter. Compliance with all known 
requirements [11, 12] for blood sampling for 
melatonin is limited by bioethics and 
compliance. 
X-ray computed tomography. The 
patients were investigated at multi detector X-ray 
tomography. Calcification was determined as 
such by its typical location and in the presence of 
at least 1 pixel with an X-ray density of ≥130 
units (Figure 1). Heterogeneity (heterogeneity 
describes changes in physical properties between 
2 or more points) of calcifications was 
determined by measuring the maximum Dmax 
and minimum Dmin of X-ray density, the 
coefficient of heterogeneity was calculated by 
the formula Cg = Dmax/Dmin. The scale 
"homogeneity → heterogeneity" Cg corresponds 
to 1.0 → 100.0. 
 
Figure 1. Patient – 59 years. Computed tomography 
image. Pineal calcification.  
 
The investigations were carried out in 
accordance with the rules and principles of 
bioethics. Patients were familiarized with the 
content of diagnostic and treatment procedures 
and signed an “Informed Consent” form. 
 Statistical processing of the material was 
carried out by methods of variation statistics. The 
values of the arithmetic mean, mean square 
(standard) error of the arithmetic mean were 
calculated. For significant differences in the 
comparison of mean values in paired 
comparisons, the Student's t-test was taken at p 
<0.01.    
 
Results and discussion 
The results of measurements and 
calculation of correlation coefficients are 
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12,9±1,2 16/100,0 754±19 7,6±0,2 
Table 2. Correlation coefficients 
Indicators Vitamin D Melatonin Volume Kg 
Vitamin D Х 0,89 - 0,90 - 0,90 
Melatonin 0,89 Х -0,79 -0,79 
Volume - 0,90 -0,79 Х 0,98 
Kg - 0,90 -0,79 0,98 Х 
In the study [10], 83 % of patients with 
bone tumors had a vitamin D deficiency – 19.82 
ng/ml. Patients with malignant tumors had 
significantly lower levels of vitamin D compared 
to patients with benign lesions (p = 0.0008). 
A study [9,10] showed that patients with 
bone metastases of breast cancer had 25-OH-D 
serum levels of 15.3 ng/ml (± 4.7 ng/ml), with 
metastatic prostate cancer – 14.7 ng/ml (± 8.3 
ng/ml), with multiple myeloma – 14.8 ng/ml (± 
6.3 ng/ml). 
The correlation analysis between the 
vitamin D content and the melatonin content 
revealed a strong direct relationship (t = 13.5; p> 
0.99), between the vitamin D content and the 
volume, between the vitamin D content and the 
coefficient of heterogeneity of calcifications - a 
strong inverse relationship (t = 14.1; p> 0.98). 
The volume and heterogeneity of 
calcifications increases, and the content of 
vitamin D and melatonin decreases in the 
examined healthy and patients in the following 
order: norm – benign tumors – malignant tumors 
– relapses/metastases. The increase in 
heterogeneity with a simultaneous increase in the 
volume of calcification may reflect the processes 
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of mineralization/demineralization in the 
calcium depot. The experiment [14] showed the 
ability of melatonin to reduce the calcification of 
the aortic valve, as evidenced by a decrease in 
thickness and calcium deposition in the valve 
leaflets, an improvement in echocardiographic 
parameters (a decrease in the maximum 
transvalvular flow velocity and an increase in the 
area of the aortic valve). Another experiment 
[15] demonstrated the reduction of vascular 
calcification and aging with the help of 
melatonin. 
 The melatonin content in blood plasma 
was studied in patients with common cancers of 
the breast, prostate, rectum, gastrointestinal tract, 
melanoma: the hormone content in all untreated 
patients was significantly lower than in healthy 
people [3,16]. The studies have practically not 
covered rare patients with malignant bone 
tumors. At the same time, high levels of 
melatonin receptors expression in human 
osteosarcomas have been established, which 
indicates an important role of melatonin in 
oncogenesis [16, 17]. The antitumor activity of 
melatonin has been studied in osteosarcomas 
[18]. 
 It is quite reasonably believed [6], that the 
calcification of the pineal gland is a marker of the 
inevitable aging process of the organism and its 
natural structure (but this is not yet generally 
accepted) is a chronicle of the specificity of 
lithogenesis. It is obvious (by analogy with 
cholelithiasis, urolithiasis, calcifying aortic valve 
disease) that slowing down this lithogenesis can 
slow down the aging process.  
 
Conclusion 
Vitamin D deficiency and pineal gland 
calcifications are observed in almost 100 % of 
patients with malignant tumors of the lower 
extremity bones. 
The high heterogeneity of calcifications 
and its dynamics during the treatment of patients 
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